Search Results - "Ooho, Aritsune"

Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real‐world cohort study by Ogawa, Eiichi, Furusyo, Norihiro, Nakamuta, Makoto, Nomura, Hideyuki, Satoh, Takeaki, Takahashi, Kazuhiro, Koyanagi, Toshimasa, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Ooho, Aritsune, Azuma, Koichi, Kato, Masaki, Shimoda, Shinji, Hayashi, Jun

“…Aim Glecaprevir (GLE) and pibrentasvir (PIB) are new direct‐acting antiviral agents (DAAs) with pangenotypic inhibitors that respectively target the hepatitis…”
Get full text

Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis by Ogawa, Eiichi, Nomura, Hideyuki, Nakamuta, Makoto, Kawano, Akira, Dohmen, Kazufumi, Kajiwara, Eiji, Satoh, Takeaki, Koyanagi, Toshimasa, Takahashi, Kazuhiro, Ooho, Aritsune, Azuma, Koichi, Furusyo, Norihiro, Kato, Masaki, Shimoda, Shinji, Hayashi, Jun

“…Aim Hepatitis C virus genotype 2 is common in East Asia, sub‐Saharan Africa, and Latin America. However, many countries in these areas lag behind other areas…”
Get full text

HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort by Tanaka, Yasuhito, Ogawa, Eiichi, Huang, Chung-Feng, Toyoda, Hidenori, Jun, Dae Won, Tseng, Cheng-Hao, Hsu, Yao-Chun, Enomoto, Masaru, Takahashi, Hirokazu, Furusyo, Norihiro, Yeh, Ming-Lun, Iio, Etsuko, Yasuda, Satoshi, Lam, Carla Pui-Mei, Lee, Dong Hyun, Haga, Hiroaki, Yoon, Eileen L., Ahn, Sang Bong, Wong, Grace, Nakamuta, Makoto, Nomura, Hideyuki, Tsai, Pei-Chien, Jung, Jang Han, Song, Do Seon, Dang, Hansen, Maeda, Mayumi, Henry, Linda, Cheung, Ramsey, Yuen, Man-Fung, Ueno, Yoshiyuki, Eguchi, Yuichiro, Tamori, Akihiro, Yu, Ming-Lung, Hayashi, Jun, Nguyen, Mindie H.

“…Background Despite HCV cure, patients remain at risk for HCC, but risk factor data for HCC following SVR are limited for Asian patients. Methods To address…”
Get full text

Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study by Ogawa, Eiichi, Nakamuta, Makoto, Koyanagi, Toshimasa, Ooho, Aritsune, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Satoh, Takeaki, Takahashi, Kazuhiro, Azuma, Koichi, Yamashita, Nobuyuki, Yamashita, Naoki, Sugimoto, Rie, Amagase, Hiromasa, Kuniyoshi, Masami, Ichiki, Yasunori, Morita, Chie, Kato, Masaki, Shimoda, Shinji, Nomura, Hideyuki, Hayashi, Jun

“…Background and aims Outcome data of sequential hepatitis B virus treatment with tenofovir alafenamide (TAF) are limited. We aimed to assess the effectiveness…”
Get full text

Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment by Yanai, Shunichi, Nakamura, Shotaro, Ooho, Aritsune, Nakamura, Shigeo, Esaki, Motohiro, Azuma, Koichi, Kitazono, Takanari, Matsumoto, Takayuki

“…Sorafenib, an oral inhibitor of multiple tyrosine kinase receptors, has been widely used as a standard medical treatment for advanced hepatocellular carcinoma…”
Get full text

Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B by Ogawa, Eiichi, Nomura, Hideyuki, Nakamuta, Makoto, Furusyo, Norihiro, Koyanagi, Toshimasa, Dohmen, Kazufumi, Ooho, Aritsune, Satoh, Takeaki, Kawano, Akira, Kajiwara, Eiji, Takahashi, Kazuhiro, Azuma, Koichi, Kato, Masaki, Shimoda, Shinji, Hayashi, Jun

“…Background and aims Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB). We aimed to assess the effectiveness…”
Get full text

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study by Ogawa, Eiichi, Nakamuta, Makoto, Koyanagi, Toshimasa, Ooho, Aritsune, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Satoh, Takeaki, Takahashi, Kazuhiro, Azuma, Koichi, Yamashita, Nobuyuki, Yamashita, Naoki, Sugimoto, Rie, Amagase, Hiromasa, Kuniyoshi, Masami, Ichiki, Yasunori, Morita, Chie, Kato, Masaki, Shimoda, Shinji, Nomura, Hideyuki, Hayashi, Jun

“…Summary Background Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus…”
Get full text

OS-062 Long-term liver morbidity and mortality after HCVelimination by direct-acting antivirals in patients with chronic hepatitis C: results from a large-scale, multicenter cohort study by Ogawa, Eiichi, Kawano, Akira, Kohjima, Motoyuki, Koyanagi, Toshimasa, Dohmen, Kazufumi, Ooho, Aritsune, Satoh, Takeaki, Takahashi, Kazuhiro, Furusyo, Norihiro, Kajiwara, Eiji, Azuma, Koichi, Ichiki, Yasunori, Sugimoto, Rie, Amagase, Hiromasa, Senju, Takeshi, Morita, Chie, Tanaka, Masatake, Nakamuta, Makoto, Nomura, Hideyuki, Hayashi, Jun

Get full text

EP101 VIROLOGICAL AND BIOCHEMICAL EFFECTIVENESS OF SEQUENTIAL NUCLEOS(T)IDE ANALOGUE TREATMENT WITH TENOFOVIR ALAFENAMIDE FOR PATIENTS WITH CHRONIC HEPATITIS B: 144-WEEK RESULTS FROM A REAL-WORLD, MULTICENTER STUDY by Ogawa, Eiichi, Nakamuta, Makoto, Koyanagi, Toshimasa, Ooho, Aritsune, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Satoh, Takeaki, Takahashi, Kazuhiro, Azuma, Koichi, Sugimoto, Rie, Amagase, Hiromasa, Senju, Takeshi, Ichiki, Yasunori, Morita, Chie, Shimoda, Shinji, Nomura, Hideyuki, Hayashi, Jun

Get full text

Development of Hepatocellular Carcinoma in Patients Aged 75–84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals by Ogawa, Eiichi, Nomura, Hideyuki, Nakamuta, Makoto, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Ooho, Aritsune, Azuma, Koichi, Takahashi, Kazuhiro, Satoh, Takeaki, Koyanagi, Toshimasa, Ichiki, Yasunori, Kuniyoshi, Masami, Yanagita, Kimihiko, Amagase, Hiromasa, Morita, Chie, Sugimoto, Rie, Kato, Masaki, Shimoda, Shinji, Hayashi, Jun

“…Abstract Background Direct-acting antiviral (DAA) treatment has revolutionized hepatitis C virus (HCV) care. We aimed to evaluate the risk for the development…”
Get full text

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study by Sugimoto, Rie, Satoh, Takeaki, Ueda, Akihiro, Senju, Takeshi, Tanaka, Yuki, Yamashita, Shinsaku, Koyanagi, Toshimasa, Kurashige, Tomoyuki, Higuchi, Nobito, Nakamura, Tsukasa, Tanaka, Masatake, Azuma, Yuuki, Ohno, Akari, Ooho, Aritsune, Ooe, Mari, Mutsuki, Taiji, Uchimura, Koutarou, Kuniyoshi, Masami, Tada, Seiya, Aratake, Yoshifusa, Yoshimoto, Tsuyoshi, Yamashita, Naoki, Harada, Shigeru, Nakamuta, Makoto, Motomura, Kenta, Kohjima, Motoyuki

“…To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted…”
Get full text

Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease by Ogawa, Eiichi, Furusyo, Norihiro, Azuma, Koichi, Nakamuta, Makoto, Nomura, Hideyuki, Dohmen, Kazufumi, Satoh, Takeaki, Kawano, Akira, Koyanagi, Toshimasa, Ooho, Aritsune, Takahashi, Kazuhiro, Kato, Masaki, Shimoda, Shinji, Kajiwara, Eiji, Hayashi, Jun

“…The real-world effectiveness and safety of all-oral direct-acting antivirals (DAAs) for chronic hepatitis C (HCV) infection and chronic kidney disease (CKD)…”
Get full text

Sa1616 MORTALITY RATES AMONG PATIENTS SUCCESSFULLY TREATED FOR HEPATITIS C: A REAL WORLD MULTINATIONAL COHORT STUDY by Enomoto, Masaru, Ji, Fanpu, Ogawa, Eiichi, Suzuki, Takanori, Huang, Chung-Feng, Wong, Yu Jun, Toyoda, Hidenori, Tran, Sally, Chuma, Makoto, Uojima, Haruki, Atsukawa, Masanori, Hsu, Yao-Chun, Jun, Dae Won, Nozaki, Akito, Tseng, Cheng-Hao, Ishigami, Masatoshi, Honda, Takashi, Trinh, Huy N., Watanabe, Tsunamasa, Abe, Hiroshi, Preda, Carmen M., Lee, Dong-Hyun, Ishikawa, Toru, Haga, Hiroaki, Liang, Jing, Takahashi, Hirokazu, Landis, Charles, Li, Jia, Takaguchi, Koichi, Senoh, Tomonori, Huang, Rui, Wong, Grace L., Wong, Vincent Wai-Sun, Lam, Carla, Huang, Daniel, Keisuke, Yokohama, Asai, Akira, Ye, Qing, Itokawa, Norio, Nakamuta, Makoto, Nomura, Hideyuki, Kajiwara, Eiji, Azuma, Koichi, Dohmen, Kazufumi, Kawano, Akira, Koyanagi, Toshimasa, Ooho, Aritsune, Satoh, Takeaki, Takahashi, Kazuhiro, Nguyen, Mindie H.

Get full text

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals by Ogawa, Eiichi, Nakamuta, Makoto, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Ooho, Aritsune, Azuma, Koichi, Takahashi, Kazuhiro, Satoh, Takeaki, Koyanagi, Toshimasa, Yamashita, Nobuyuki, Ichiki, Yasunori, Yamashita, Naoki, Kuniyoshi, Masami, Yanagita, Kimihiko, Amagase, Hiromasa, Morita, Chie, Sugimoto, Rie, Kato, Masaki, Shimoda, Shinji, Nomura, Hideyuki, Hayashi, Jun

“…Background and Aim Early hepatocellular carcinoma (HCC) recurrence is common, even after achieving hepatitis C virus (HCV) cure. This study was carried out to…”
Get full text

Long‐term hepatic function of patients with compensated cirrhosis following successful direct‐acting antiviral treatment for hepatitis C virus infection by Ogawa, Eiichi, Kawano, Akira, Ooho, Aritsune, Furusyo, Norihiro, Satoh, Takeaki, Takahashi, Kazuhiro, Kajiwara, Eiji, Dohmen, Kazufumi, Nakamuta, Makoto, Azuma, Koichi, Koyanagi, Toshimasa, Yamashita, Nobuyuki, Yanagita, Kimihiko, Ichiki, Yasunori, Kuniyoshi, Masami, Yamashita, Naoki, Morita, Chie, Sugimoto, Rie, Kato, Masaki, Shimoda, Shinji, Nomura, Hideyuki, Hayashi, Jun

“…Background and Aim Direct‐acting antivirals (DAAs) have contributed to the improvement of outcomes for all patients with chronic hepatitis C. The aim of this…”
Get full text

Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication by Ogawa, Eiichi, Toyoda, Hidenori, Iio, Etsuko, Jun, Dae Won, Huang, Chung-Feng, Enomoto, Masaru, Hsu, Yao-Chun, Haga, Hiroaki, Iwane, Shinji, Wong, Grace, Lee, Dong Hyun, Tada, Toshifumi, Liu, Chen-Hua, Chuang, Wan-Long, Hayashi, Jun, Cheung, Ramsey, Yasuda, Satoshi, Tseng, Cheng-Hao, Takahashi, Hirokazu, Tran, Sally, Yeo, Yee Hui, Henry, Linda, Barnett, Scott D, Nomura, Hideyuki, Nakamuta, Makoto, Dai, Chia-Yen, Huang, Jee-Fu, Yang, Hwai-I, Lee, Mei-Hsuan, Jun, Mi Jung, Kao, Jia-Horng, Eguchi, Yuichiro, Ueno, Yoshiyuki, Tamori, Akihiro, Furusyo, Norihiro, Yu, Ming-Lung, Tanaka, Yasuhito, Nguyen, Mindie H

“…Abstract Background Cure rates of hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) for patients with active and inactive hepatocellular…”
Get full text

FRI430 - Development of hepatocellular carcinoma by patients aged 75 years or over after HCVelimination by all-oral DAA therapy: results from a large-scale, multicenter cohort study by Ogawa, Eiichi, Hideyuki, Nomura, Nakamuta, Makoto, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Ooho, Aritsune, Azuma, Koichi, Takahashi, Kazuhiro, Satoh, Takeaki, Koyanagi, Toshimasa, Ichiki, Yasunori, Kuniyoshi, Masami, Yanagita, Kimihiko, Amagase, Hiromasa, Morita, Chie, Sugimoto, Rie, Kato, Masaki, Shimoda, Shinji, Hayashi, Jun

Get full text

Development of hepatocellular carcinoma by patients aged 75 years or over after HCVelimination by all-oral DAA therapy: results from a large-scale, multicenter cohort study by Ogawa, Eiichi, Hideyuki, Nomura, Nakamuta, Makoto, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Ooho, Aritsune, Azuma, Koichi, Takahashi, Kazuhiro, Satoh, Takeaki, Koyanagi, Toshimasa, Ichiki, Yasunori, Kuniyoshi, Masami, Yanagita, Kimihiko, Amagase, Hiromasa, Morita, Chie, Sugimoto, Rie, Kato, Masaki, Shimoda, Shinji, Hayashi, Jun

Get full text

SAT-254-Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study by Ogawa, Eiichi, Furusyo, Norihiro, Hideyuki, Nomura, Dohmen, Kazufumi, Takahashi, Kazuhiro, Nakamuta, Makoto, Kawano, Akira, Satoh, Takeaki, Ooho, Aritsune, Azuma, Koichi, Koyanagi, Toshimasa, Kajiwara, Eiji, Ichiki, Yasunori, Kuniyoshi, Masami, Yanagita, Kimihiko, Amagase, Hiromasa, Morita, Chie, Sugimoto, Rie, Shimoda, Shinji, Kato, Masaki, Hayashi, Jun

Get full text

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C by Ogawa, Eiichi, Nomura, Hideyuki, Nakamuta, Makoto, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Ooho, Aritsune, Azuma, Koichi, Takahashi, Kazuhiro, Satoh, Takeaki, Koyanagi, Toshimasa, Ichiki, Yasunori, Kuniyoshi, Masami, Yanagita, Kimihiko, Amagase, Hiromasa, Morita, Chie, Sugimoto, Rie, Kato, Masaki, Shimoda, Shinji, Hayashi, Jun

“…Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients…”
Get full text